The dental diagnostic AI market has consolidated around two clear frontrunners: Pearl’s Second Opinion and Overjet’s clinical AI platform. Both hold FDA clearances for radiographic analysis, both are deployed across thousands of dental practices, and both are actively competing for DSO contracts. For dental service organizations evaluating chairside AI, the differences between these two products are nuanced but meaningful. This is a detailed product-level comparison to help DSO technology leaders make an informed decision.
FDA Clearance and Clinical Scope
Pearl’s Second Opinion has received multiple FDA clearances and can detect a wide range of pathologies on dental radiographs, including caries, periapical lesions, calculus, and other common conditions. Pearl reports that its system can identify over 100 conditions across various radiograph types including bitewings, periapicals, and panoramic images. The breadth of detectable conditions is one of Pearl’s strongest differentiators.
Overjet also holds FDA clearances for its dental AI analysis, with a focus on caries detection and bone level quantification. Overjet’s particular strength is in periodontal assessment, where its AI provides quantitative measurements of bone loss that can be tracked longitudinally. This capability is especially valuable for DSOs that want to standardize periodontal diagnoses across providers and locations. Overjet has also expanded into dental insurance, where its AI is used by payers to review claims, giving it a unique dual-sided market position.
How Each Tool Works at Chairside
Pearl Second Opinion is designed to operate as a real-time diagnostic overlay. When a radiograph is captured, Second Opinion analyzes the image and presents annotated findings directly on the image within seconds. The tool highlights detected pathologies with color-coded outlines and confidence indicators, giving the clinician an AI-generated “second opinion” before or during the patient consultation. This visual presentation has proven effective for case acceptance, as patients can see the AI’s findings alongside the dentist’s explanation.
Overjet’s clinical platform similarly analyzes radiographs in real time and provides annotated overlays. Its bone level measurement feature draws quantitative lines on the radiograph indicating the distance from the CEJ (cemento-enamel junction) to the bone crest, expressed in millimeters. This quantitative approach is particularly useful for periodontal treatment planning and for documenting disease progression over time. Overjet’s output is structured and measurable, which appeals to clinicians and compliance teams who value standardized, quantifiable diagnostic data.
Integration and Deployment
Both platforms integrate with major PMS and imaging systems. Pearl supports integrations with Dentrix, Eaglesoft, Open Dental, and various imaging software platforms. Overjet maintains similar PMS compatibility and has built integrations with leading imaging systems. For DSOs, the critical question is whether the AI tool integrates with your specific PMS and imaging stack without requiring significant custom development.
Deployment models differ slightly. Pearl Second Opinion can operate as a cloud-based analysis engine, where images are sent to Pearl’s servers and results returned in seconds. Overjet similarly uses cloud-based processing. Both require reliable internet connectivity at each practice location, which is a non-issue for most modern dental offices but worth verifying for locations in areas with limited bandwidth.
Impact on Treatment Acceptance and Revenue
Both vendors report that their AI tools increase treatment acceptance rates. The mechanism is straightforward: when a patient sees an AI-generated annotation highlighting a cavity or bone loss on their own radiograph, and the dentist explains the finding, the combination of human expertise and AI validation builds trust. Pearl has published data suggesting significant increases in case acceptance among practices using Second Opinion. Overjet has reported similar improvements, particularly in periodontal treatment acceptance where the quantitative bone loss measurements provide compelling visual evidence.
For DSOs, the revenue impact of diagnostic AI extends beyond treatment acceptance. Standardized AI-assisted diagnostics reduce variability between providers, which means fewer missed diagnoses and more consistent care quality across locations. This consistency is valuable not only for patient outcomes but also for DSO brand reputation and risk management.
Insurance and Payer Relationships
Overjet has a distinctive strategic advantage in the payer market. The company has deployed its AI to dental insurance companies for claims review, meaning the same AI technology used by providers to diagnose conditions is also used by insurers to validate claims. This dual positioning has interesting implications for DSOs: if the insurer’s AI and the provider’s AI agree on the diagnosis, claim disputes may decrease. Overjet has leaned into this narrative, positioning itself as a bridge between providers and payers.
Pearl has focused primarily on the provider side, building its market position around clinical decision support and practice growth. While Pearl’s AI-generated findings can support claims documentation, the company has not pursued the payer market as aggressively as Overjet.
Pricing and ROI Considerations
Both vendors typically price on a per-location, per-month subscription basis, with volume discounts for larger DSOs. Exact pricing varies based on contract size and negotiation, but DSOs should expect to invest meaningfully for enterprise-wide deployment. The ROI calculation for both tools centers on increased production from higher treatment acceptance, fewer missed diagnoses, and improved documentation that supports claims.
Making the Decision
Both Pearl Second Opinion and Overjet represent the leading edge of dental diagnostic AI. Pearl’s strength lies in the breadth of its detectable conditions and its focus on the chairside patient experience. Overjet’s strength lies in its quantitative periodontal capabilities and its unique provider-payer dual positioning. DSOs with a strong periodontal focus or those that want alignment between their diagnostic AI and what insurers are using may lean toward Overjet. DSOs prioritizing the broadest possible pathology detection and patient communication impact may prefer Pearl.
It is also worth noting that diagnostic AI is just one layer of the AI stack DSOs are building. These clinical tools work best when paired with AI-driven patient communication platforms, such as Viva AI for front office automation or VideaHealth for additional imaging intelligence, creating a connected workflow from diagnosis through treatment acceptance and follow-up. The future belongs to DSOs that think about AI as a system, not a single tool.